Wnt signaling is important for embryonic development and adult tissue homeostasis, and these distinct functions are mediated by a plethora of intracellular signaling cascades divided into two main categories: canonical and non-canonical Wnt pathways.
| OVERVIE W OF WNT-REL ATED PS EUDOKINA S E S
Wnt signaling is important for embryonic development and adult tissue homeostasis, and these distinct functions are mediated by a plethora of intracellular signaling cascades divided into two main categories: canonical and non-canonical Wnt pathways. 1 Canonical Wnt signaling promotes the β-catenin-dependent TCF/LEF (T-cell factor/ lymphoid enhancer-binding factor) pathway or β-catenin independent Wnt/STOP (Wnt/stabilization of proteins) signaling through Frizzled and LRP5/6 (low-density lipoprotein receptor-related proteins 5/6) receptors to mainly regulate cell differentiation and proliferation. to regulate cell polarity, adhesion, and motility. 3 Wnt ligands are secreted Cys-rich proteins that can bind to various Wnt receptors to activate both β-catenin -dependent and/or -independent pathways, although the activity of many Wnts depends on the cellular context and (co-)receptor expression, which determines the downstream pathway and ultimate functional effect. 4 Several Wnt ligand-binding receptors belong to the pseudokinase family, such as RORs, PTK7, and RYK ( Figure 1 ), which are mediators of non-canonical Wnt signaling. 5 These members of the receptor tyrosine kinase family have an intracellular tyrosine kinase-like domain devoid of ATP-binding and catalytic activity due to mutations in the canonical motifs required for proper kinase activation. 6, 7 Despite their altered structural and enzymatic properties, these pseudokinases retain their ligand-induced signaling abilities. This is achieved either by allosterically modulating the activity of other kinases or by recruitment/scaffolding of intracellular signaling molecules to modulate an array of functional mechanisms such as cell polarity, cell motility, migration, and chemotaxis. 1, [8] [9] [10] Interestingly, higher expression levels of these Wnt-binding receptor pseudokinases in different hematological cancers have prompted in depth studies of their oncogenic role in sustaining cancer cell survival and therapy resistance. [11] [12] [13] [14] In recent years, significant progress has been made using preclinical and clinical models to demonstrate their potential in targeted therapies for cancer treatment, including hematological cancers, which are the focus of this review. indicating that these proteins can become useful markers for diagnosis and/or targets for treatment purposes that will be discussed below.
| E XPRE SS I ON ANALYS IS OF ROR S , P TK 7, AND RYK IN HE ALTHY AND MALIG NANT HEMATOLOG IC AL TISSUE S

| ROR S I G NALING IN HEMATOLOG I C AL CELL S
ROR1 and ROR2 belong to the ROR family of single transmembrane receptors, which have crucial roles in embryonic and fetal development. 19 kinase) pathway. [20] [21] [22] The ROR kringle domain was shown to be important for receptor heterodimerization in response to Wnt5a binding in vitro 22 ; however, its role in vivo is still elusive. The intracellular domains (ICDs) of RORs include a tyrosine kinase-like domain followed by two serine/threonine-rich domains flanking a proline-rich domain, and a short C-terminus end ( Figure 1 ). RORs are considered pseudokinases due to mutation in the canonical motifs found in bona fide kinases and the lack of detectable kinase activity in vitro using purified recombinant proteins. 6, 23 /NFAT/NF-κB/BCL-6 signalosome, suggesting an important role for it in modulating B-cell functions. 26 As Wnt5a binds to other receptors beside RORs (such as PTK7 and RYK), its expression and functional output are wider and defined by the receptor constellation present in a particular cell type. 29 For example, the functional interaction between Wnt5a and RYK regulates quiescence of HSC by inhibiting formation of reactive oxygen species (ROS). 17 The signal specificity of Wnt5a and its various receptors still needs further investigation.
Considerable progress in deciphering ROR1 signaling in leukemic cells has been made in CLL models, indicating that Wnt5a induces ROR1/ROR2 oligomerization and Rho/Rac GTPases activation in CLL cells. 22 Moreover, the ROR1 Pro-rich domain interacts with hematopoietic lineage cell-specific protein 1 (HS1) to drive F-actin polymerization and cell migration, whereas the first Ser/Thr-rich domain in ROR1 could bind the 14-3-3ζ protein to induce activation of RhoA/Rac1 and the enhancement of leukemic cell proliferation and migration. 30, 31 Furthermore, in a separate study, Cordon-bleu protein-like 1 (COBLL1) was identified as ROR1 binding partner and independent prognostic marker for CLL. 32 High levels of Wnt5a in CLL cells increase leukemic cell migration and chemotactic response compared to CLL cells with low or no Wnt5a expression and correlate F I G U R E 2 Gene expression of Wnt-related pseudokinases in healthy (left) and cancerous (right) hematological tissues derived from IST Online™ (ist.medisapiens.com). Data presented as box-whisker blots, where the bottom of the box is the 25th percentile of the data, the top of the box is the 75th percentile, and the horizontal line is the median. The whiskers extend to 1.5 times the interquartile range from the edges of the box, and any data points beyond this are considered outliers, marked by hollow circles 80 [Colour figure can be viewed at
with worse prognosis. 33 Wnt5a can be produced by CLL cells in an autocrine fashion or can be secreted by the microenvironment to enhance chemotaxis of CLL cells via activation of Rho/Rac GTPases after engagement of ROR receptors. 22 Therefore, it appears that in CLL Wnt5a orchestrates its intracellular signaling via ROR receptors to drive leukemic cell migration and invasion. Interestingly, another study in CLL models has uncovered a direct link between ROR1 expression and STAT3 activation. 34 A STAT3-binding site in the ROR1
promoter sustained STAT3-dependent ROR1 expression, while IL6-mediated activation of STAT3 resulted in upregulated ROR1 protein levels. The same positive correlation between ROR1 and STAT3 expression was also described in B-ALL cells, showing that upregulation of ROR1 levels increased STAT3 phosphorylation. 24 In MCL (mantle cell lymphoma) models, Wnt5a-ROR1 expression was found to be associated with canonical NF-κB pathway activation and drug resistance. 35 This is supported by the presence of NF-κB binding sites in the promoters of both Wnt5a and ROR1, providing a feedback activation loop Wnt5a/ROR1/NF-κB p65 regulating cell proliferation, survival, and drug resistance. (supported by Oncternal Therapeutics). Cirmtuzumab was shown to be effective in preclinical models and to reduce the engraftment of ROR1 + leukemic cells in a transgenic mouse model, while mAbassociated cytotoxicity was not detected in healthy animals. 38 The ADC therapy took advantage of the internalization properties of anti-ROR1 mAb 2A2, 39 which has some cytotoxic levels in vitro 35, 41 due to its internalization and downregulation of ROR1 levels, to create the novel non-immunosuppressive derivative OSU-2S, which effectively impairs CLL cell survival via activation of protein phosphatase 2A (PP2A) in leukemic cells. 42 On the other hand, given the promising results in clinical trials of CD19 CAR-T cells 43, 44 and suggesting that other pathways than NF-κB could be responsible for altering ROR1 levels, and should be investigated. 35 It is important to understand that successful co-targeting of ROR1 and the BCR pathway depends on BCR sensitivity in MCL models, and that modulation of ROR1 levels by BCR targeted drugs should be considered in clinical settings.
| TARG E TING BCL-2 FAMILY AND ROR1 IN COMB INATORIAL TRE ATMENTS
shRNA-mediated ROR1 targeting combined with DSRT in both BCRsensitive and BCR-insensitive MCL cells enhanced cytotoxicity for several apoptotic modulators such as Bcl-2 family inhibitors. This was especially true for BH3 mimetics navitoclax and venetoclax, 35 currently used in the clinic, and this effect was also observed in CLL. 58 These findings bring to our attention another combinatorial treatment with excellent clinical potential, which can target ROR1
and Bcl-2 and may have additive, if not synergistic, responses in CLL and MCL patients.
| P TK S I G NALING IN HEMATOP OIE TI C CELL S
PTK7 is another member of the Wnt-related pseudokinases that has seven extracellular immunoglobulin-like domains, a transmembrane domain, and an intracellular catalytically inactive tyrosine kinase-like domain ( Figure 1 ). 1 The ectodomain of PTK7 can be proteolytically cleaved by MT1-MMP (membrane type-1 matrix metalloproteinase)
and ADAMs (a disintegrin and metalloproteinases) resulting in soluble PTK7 fragments being released from the cells, which can affect cytoskeleton organization contributing to cell invasion. 59, 60 Although the signaling mechanism of PTK7 is largely unknown, PTK7 is strongly associated with PCP pathway regulation. Based on loss-of-function data in mice and Xenopus, PTK7 is required for neural tube closure and stereociliary bundle orientation during development in vertebrates.
61
PTK7 recruits DVL to the plasma membrane, channeling DVL signaling toward the PCP pathway via Frizzled-7. 62 PTK7 was shown to interact with ROR2 and Wnt5a or Wnt3a in order to activate non-canonical and inhibit canonical Wnt signaling, although more studies are needed to understand its specific interaction and functional roles within Wnt pathway regulation. [63] [64] [65] Within the hematopoietic tissue, PTK7 expression appears to be although it has no effect on cell differentiation. 66 Lack of PTK7 in PTK7-deficient mice was associated with an increased quiescence and enhanced long-term establishment of hematopoiesis, underlining a role for this pseudokinase in stem cell biology. 66 Dysregulated expression of PTK7 is observed in several hematological malignancies and solid tumors. In hematological malignancies, varying levels of PTK7
were observed in AML, B-ALL, and T-ALL. 12, 66, 67 Approximately twothirds of AML blasts express PTK7 potentially making it a prognostic marker, and its expression has been associated with a bad prognosis and an increased early relapse rate. 12 Furthermore, PTK7 expression increases chemotherapeutic resistance to anthracycline-based drugs such as doxorubicin, a process that could be reversed by blocking PTK7 signaling with an Fc-PTK7 soluble protein. 12 Altogether, these data provide evidence for a role for PTK7 in drug resistance and suggest that the use of PTK7 agonists or antagonists should be explored for therapeutic purposes in leukemia/cancer treatment.
| RYK S I G NALING IN HEMATOP OIE TI C CELL S
RYK is another receptor pseudokinase from the non-canonical It also inhibited co-immunoprecipitation of RYK with Wnt5a but not with Wnt3a, potentially indicating a Wnt-specific mechanism of antagonism. 69 The development of more specific antibodies could help us in deciphering RYK signaling in healthy and malignant tissues.
| CON CLUS IONS
Significant progress has been made in the last decade in deciphering the structural and functional mechanisms of pseudokinases, demonstrating that these proteins are central components of signal transduction networks and contribute to cell signaling in normal and disease conditions, making them highly attractive therapeutic targets.
Despite lacking enzymatic functions, RORs, PTK7, and RYK still bind 
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